Key result
Treatment with the oral endothelin receptor antagonist bosentan controlled pulmonary hypertension and improved renal function in a 14-year-old boy with thrombotic microangiopathic nephropathy.
Why the study?
Does bosentan improve pulmonary hypertension and renal function in a pediatric patient with thrombotic microangiopathic nephropathy?
Case Report (n=1)
Does bosentan improve pulmonary hypertension and renal function in a pediatric patient with thrombotic microangiopathic nephropathy?
Bosentan may have a therapeutic role in managing both pulmonary hypertension and microangiopathic nephropathy in patients with coexisting conditions.
Answers are grounded in this paper and cite their sources.
First pediatric TMA nephropathy-pulmonary hypertension case without malignancy; leaves open a possible new association requiring confirmation.
The coexistence of thrombotic microangiopathic nephropathy and pulmonary hypertension has only been described in association with malignancy and its treatment. Here we describe a 14-year-old boy with no prior medical history who presented with hypertension, proteinuria and nephromegaly, and then developed progressive pulmonary hypertension. Renal histology showed lesions consistent with glomerulopathy due to thrombotic microangiopathy (TMA). Pulmonary hypertension was controlled by the use of an oral endothelin receptor antagonist (bosentan). Although renal function deteriorated at the onset of pulmonary hypertension, an improvement was observed after the bosentan treatment. Nephromegaly persisted, but current creatinine clearance values are within the normal range. While this case exemplifies how thrombotic microangiopathic nephropathy may be associated with pulmonary hypertension, a therapeutic role of endothelin antagonists is suggested, not only for pulmonary hypertension but also for microangiopathic nephropathy.
No takes yet. Share an insight, caveat, or question.
Losito et al. (2011) conducted a case report in Thrombotic microangiopathic nephropathy and pulmonary hypertension (n=1). Bosentan was evaluated. Treatment with the oral endothelin receptor antagonist bosentan controlled pulmonary hypertension and improved renal function in a 14-year-old boy with thrombotic microangiopathic nephropathy.
Synapse has enriched 10 related papers. Consider them for comparative context: